Stratifind

About the offering

Stratifind, Inc. (operating as STRATIFIND) is an early-stage precision oncology diagnostics company developing an asset-light, next-generation sequencing (NGS)-based platform called RainDanceEQ™. The company was co-founded by Dr. Partha S. Ray, a surgical oncologist with 15+ years of frontline cancer care and over 5,000 complex tumor surgeries, and Igor Sokolovsky, a healthcare investment banker with over $170 billion in completed transactions across diagnostics and life sciences. Core Technology: RainDanceEQ™ is a multi-omic cancer diagnostic test that integrates DNA mutation data with RNA expression signals to produce a ranked, actionable therapy recommendation for oncologists. Unlike legacy DNA-only tests that identify eligible therapies, RainDanceEQ™ aims to indicate which therapy should be used first based on actual tumor behavior. The platform's predictive algorithms were developed using 20,000+ tumor samples and 15+ years of foundational research. Initial cancer indications include Lung, Breast, Colon, and Melanoma, with planned expansion into Prostate, Kidney (RCC), Liver (HCC), Bladder, and Head & Neck cancers. Operating Model: STRATIFIND is designed as an asset-light, B2B2C platform. Wet-lab sequencing (DNA/RNA extraction and NGS) is intended to be performed by CLIA-certified laboratory partners, while STRATIFIND focuses on the bioinformatics, data interpretation, report generation, and billing layers. The company is targeting a Florida-based CLIA dry-lab framework by end of 2026. A wet-lab partner agreement is under discussion. No FDA approval is stated to be required for initial commercial deployment as a laboratory-developed test (LDT). Reimbursement Strategy: The company plans to bill Medicare and commercial insurance from day one using established CPT/coding frameworks at an anticipated reimbursement price of approximately $2,500 per test. Future pursuit of dedicated PLA coding to reflect differentiated value is mentioned as a possibility pending additional clinical utility data. Clinical Validation: Lung cancer results are being prepared for publication and submission to major oncology conferences (ASCO, ESMO, IASLC) in collaboration with physicians at Massachusetts General Hospital. Full analytical validation is planned to confirm accuracy, consistency, and reliability. The platform has been designed to fit into existing oncology workflows at two key clinical decision points: pre-surgical biopsy and post-surgical tissue analysis. Market Opportunity: The company estimates an initial TAM of approximately $1.0 billion per year (Stage 1: Lung, Breast, Colon, Melanoma at ~400,000 tests/year) expanding to approximately $2.15 billion per year across a full multi-cancer platform (Stage 3). The SAM for Stage 1 is estimated at ~$550 million. Team: The leadership team includes Dr. Ray (CMO/Chairman), Igor Sokolovsky (CEO), and Dr. Yury Takhalov (Laboratory Medical Director, board-certified pathologist). The advisory board includes Dr. Luke C. Peng (radiation oncology, Harvard Medical School faculty) and Michael Wentzien (former senior managed care executive advising on reimbursement and market access). Use of Proceeds: If the maximum raise of $450,001 is achieved, funds are allocated primarily to Sales & Marketing (33.3%), Manager Compensation (27.8%), R&D and Product Development (5.6%), Validation of RainDanceEQ™ (8.9%), Working Capital (4.4%), Fractional Accountant (4.4%), and Intermediary Fees (4.9%), among other uses. Current Status: The company has raised $28,094 on Netcapital against a minimum target of $10,000, with a deadline of June 26, 2026. The offering is Regulation CF Common Stock at $2.38 per share, implying a post-money valuation of approximately $12.35 million at maximum raise. Financial statements have been reviewed by an independent CPA.

FAQ